Elanco Animal Health, Inc. Stock News

MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Deve...

The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.

EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovation Action reinforces the FDA's commitment to act swiftly against emerging animal health th...

INDIANAPOLIS , Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, December 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference at 12:30 p.m.

Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS , Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to create and scale new companies at the convergence of animal, plant and human health in partnership with  Elanco Animal Health (NYSE: EL...

Elanco Animal Health Incorporated ( ELAN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tiffany Kanaga Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Andrea ...

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% organic constant currency growth Reported Net Loss of $34 million, Adjusted Net Income of $94 million Adjusted EBITDA of $198 million; Adjusted EBITDA Margin of 17.5%  Reported EPS of $(0.07), Adjuste...

FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i  The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far t...